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Abstract
Background: Suboptimal thyroid hormone therapy including under-replacement and over-replacement is common
amongst patients with hypothyroidism. This is a significant health concern as affected patients are at risk of adverse
cardiovascular or metabolic consequences. Despite a growing body of evidence on the effects of various factors on
thyroid hormone replacement, a systematic appraisal of the evidence is lacking. This review aims to appraise and
quantify the extent to which clinical, behavioural and pharmacogenomic factors affect levothyroxine therapy in
patients with primary hypothyroidism.
Methods/design: The databases Web of Science, Cochrane Library, EMBASE and PubMed will be searched. Patients
must be adults over the age of 18 years, suffering from primary hypothyroidism including overt and subclinical
hypothyroidism and receiving levothyroxine treatment. Studies in children, pregnant women and patients with
secondary or tertiary hypothyroidism will not be included. We will also exclude studies focused on forms of thyroid
hormone replacement therapy other than levothyroxine.
The primary outcome is to quantify the effect of clinical, behavioural and pharmacogenomic factors on thyroid
stimulating hormone (TSH) levels. Secondary outcomes are the effect these factors have on thyroxine (T4) and
triiodothyronine (T3) levels, mortality, morbidity, quality of life, treatment complications, adverse effects, physical and
social functioning. Studies will be screened through reading the title, abstract and then full text. Two reviewers will
independently extract the data and select articles, and a third reviewer will be consulted if there is any disagreement.
We will undertake a meta-analysis of studies in which there is a defined intervention or exposure, patients are receiving
levothyroxine for hypothyroidism, there is an appropriate control group of levothyroxine treated patients that are not
exposed to the intervention, and the primary outcome is determined by serum TSH levels. Studies will comprise of
randomised controlled trials as well as observational data.
Eligible studies will be assessed for bias using the risk of bias tool available in the Cochrane handbook 2011, and the
quality of evidence will be judged according to the Grading of Recommendations Assessment, Development, and
Evaluation (GRADE) approach. A flow diagram describing the data search will be created according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis: The PRISMA statement. A narrative synthesis will be
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undertaken in the description of the data, and summary tables will be created of the results.
Discussion: This review will be the first systematic review of this nature. The evidence synthesised will be useful to
general practitioners in their management of hypothyroidism. Findings will be disseminated at conferences and in
professional and peer-reviewed journals.
Systematic review registration: PROSPERO CRD42015027211
Keywords: Primary hypothyroidism, Subclinical hypothyroidism, Levothyroxine, TSH
Background
Hypothyroidism is a common disease affecting 3–5% of
the population and is the result of insufficient produc-
tion of thyroid hormones. Over 99% of hypothyroid
cases are caused by primary hypothyroidism or inad-
equate function of the thyroid gland [1, 2]. Within the
thyroid disease free population, the reference range for
thyroid stimulating hormone, thyrotropin (TSH), is com-
monly between 0.4 and 4.0 mU/L, and levels above this
are indicative of hypothyroidism. Overt hypothyroidism
is a clinical condition in which TSH is increased above
the reference range, and free thyroid hormones, most
significantly thyroxine (T4), are low, while subclinical
hypothyroidism (SCH) refers to TSH levels above the
normal reference range, but free thyroid hormones are
within their reference range [3].
Three percent of the UK population receive thyroid hor-
mone replacement therapy [4]. Synthetic levothyroxine is
commonly used, and the goal of therapy is to achieve clin-
ical wellbeing and restore serum TSH levels to within the
reference range. Levothyroxine has a long half-life of about
7 days, and so, a once daily dose provides stable and rela-
tively constant serum hormone levels. With individual dos-
age adjustment, levothyroxine replacement therapy is safe
and well tolerated [5]. However, over a third of patients
with hypothyroidism are inadequately treated i.e. under-
treated or over-treated, as shown by abnormal serum TSH
levels in community-based cohorts of levothyroxine treated
patients [6, 7]. This problem has persisted for decades and
remains an issue even with frequent biochemical monitor-
ing of patients [8–10]
Patients with inadequate replacement have an increased
risk of cardiovascular events, fractures [11–13], dyslipidae-
mia [14], neurocognitive dysfunction [15] and in extreme
cases, may develop the life threatening state of myxoe-
dema coma [16]. In addition, there are healthcare resource
implications of having abnormal thyroid biochemistry as
these patients are more likely to need their blood tests re-
peated, have frequent adjustments to their levothyroxine
dose, experience recurrent symptoms affecting well-being
and quality of life, and contribute to prescription wastage
from poor adherence to treatment. Reduced quality of life
is very common amongst hypothyroid patients, particu-
larly relating to energy, motivation, physical capabilities,
physical appearance and weight [17]. Furthermore,
hypothyroid patients even with apparently normal TSH
levels report having reduced psychological well-being [18]
and poor quality of life [19]. To what extent thyroid hor-
mone levels have a causative role in the symptoms in these
cases remains to be determined.
There is now a growing body of evidence describing
the effects of a variety of factors on thyroid hormone
therapy. Some of these factors include body weight,
pregnancy, co-morbid conditions, consistency and qual-
ity of levothyroxine, drug interactions and dose timings,
and behavioural factors such as adherence rates. Phar-
macokinetic factors also play a role since levothyroxine
is absorbed from the stomach, and small bowel and its
optimal absorption is dependent on the acidic environ-
ment of the stomach. Several factors are known to per-
turb absorption through this mechanism, including the
use of calcium or iron salts, proton pump inhibitors,
atrophic gastritis (pernicious anaemia) and coeliac dis-
ease [20, 21]. Pharmacogenomic associations may also
be relevant to the adequacy of thyroxine therapy, and
the evidence in this area is increasing. For example,
within the metabolic pathway of thyroxine, polymor-
phisms in the type 2 deiodinase, DIO2, (Thr92Ala) has
been shown to influence the levothyroxine dose required
to achieve target TSH levels [22].
Thus, there will undoubtedly be multifactorial reasons for
poor response to therapy in patients with hypothyroidism.
This review aims to summarise the contemporary literature
and quantify the extent that clinical, behavioural and phar-
macogenomic factors affect the response to levothyroxine
and contribute to abnormal TSH levels in patients with pri-
mary hypothyroidism.
Methods/design
The systematic review including its methodology will be
reported according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis: The PRISMA
statement [23]. The PRISMA statement refers to a
checklist, which includes items deemed essential for pre-
cise reporting of a systematic review. The additional file
shows this in more detail (Additional file 1).
Since there are a variety of factors associated with the
response to levothyroxine therapy, this review will adopt
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a broad approach to answering the review question. Eli-
gibility criteria will ensure hypothyroid patients as the
population of interest and the effect on TSH as the pri-
mary outcome focus. A summary of participants, inter-
ventions, comparators, outcomes and study design
(PICOS) details are outlined in Table 1.
Types of studies
Findings from preliminary searches using the keywords
hypothyroidism, TSH, food, comorbid, concomitant,
compliance, levothyroxine, drugs and OATP1, MCT,
UGT, FOXE and deiodinase genes in Web of Science
database showed a large variation in the study design
used in articles, and the articles consist mainly of non-
randomised studies (NRT). Following Cochrane handbook
guidance, risk of bias, confounding and heterogeneity will
be considered for the type of studies to be used in our re-
view [24]. Since our systematic review needs to have a
broad approach to cover a wide range of factors, all stud-
ies will be included within our search; RCTs, case-control,
cohort, cross sectional, longitudinal, observational and
case studies. This will enable evaluation of interventions
that were not studied using a RCT design and therefore
allows a wide spread of data to be analysed. However, we
will take into account design weaknesses as well as the po-
tential for selection bias, outcome reporting bias and con-
founding of which all NRS are at risk. We will include full
journal articles published in English with sufficient data
presented in abstracts. Studies will be required to compare
TSH levels of hypothyroid patients with or without the in-
terventions defined below.
Participants
Human participants aged 18 years or older diagnosed with
primary hypothyroidism, whether overt or subclinical, and
receiving levothyroxine therapy. Exclusion criteria are
cited in Table 1.
Interventions
Interventions addressing factors that may affect the ad-
equacy of levothyroxine therapy in the hypothyroid
population will be included. Selected studies will involve
interventions of any type, frequency and intensity that
modify clinical, pharmacological or behavioural factors,
including studies based on pharmacogenomic character-
istics that may affect levothyroxine availability. Such
interventions will include measures that influence thy-
roxine pharmacokinetics, such as drug administration
dosage and scheduling, drug interactions, management
of co-morbid conditions, and measures designed at im-
proving medication adherence. Interventions will be re-
quired to have duration of greater than 6 weeks, and the
effectiveness of the intervention on levothyroxine ther-
apy will be measured by TSH levels. Interventions are
grouped as:
Table 1 Summary of the PICOS elements included in the systematic review
Inclusion criteria Exclusion criteria
Population/patients Human subjects Animals
18 years or older Children
Patients with diagnosed primary hypothyroidism
or subclinical hypothyroidism
Pregnant women/patients with secondary or tertiary
hypothyroidism/hyperthyroid patients/patients previously
treated for thyroid cancer
Receiving levothyroxine treatment Other forms of hormone replacement therapy/
combination therapy
Intervention Interventions of any type, intensity and frequency, with
length greater than 6 weeks used to investigate effect
of clinical, behavioural or pharmcogenomic factors on
levothyroxine therapy
N/A
Comparators/control A control or comparative group is necessary. This can
be placebo/no treatment/standard therapy/usual
care/alternative treatment
No control/comparative group
Outcome Primary outcome; quantitative effect of clinical/
behavioural/pharmacogenomic factors on TSH levels
Secondary outcome (s); quantitative effect of
clinical/behavioural/
Pharmacogenomics factors on T4 and T3 levels/any
short term effects/mortality/morbidity/quality of life/
treatment complications/adverse effects/rate of relapse/
physical functioning/social functioning
Reviews only focused on the quantitative effect of clinical/
behavioural/
Pharmacogenomics factors on T4 and T3 levels
Study design RCTs, case-control studies, cohort studies, observational
studies, cross sectional studies, longitudinal studies,
case studies
N/A
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 Concomitant medications taken with levothyroxine:
proton pump inhibitors, omeprazole, lansoprazole,
lanthanum carbonate, calcium, antacids, sevelamer
hydrochloride, cholestyramine, colsevelam, ferrous
sulphate and aluminium hydroxide.
 Behavioural factors that could affect levothyroxine:
dose timing, compliance, adherence, attitudes and
perceptions.
 Co-morbidities present in hypothyroid patient:
lactose intolerance, coeliac disease, gastritis, type 2
diabetes, pancreatic disease, liver disease and
pernicious anaemia
 Pharmacogenomic factors that may impact on
levothyroxine bioavailability: OATP1, MCT, UGT,
FOXE and deiodinase genes
Studies must report results of the effects of interventions
on TSH levels, and if also provided T4 and Triiodothyron-
ine (T3) levels, as well as the effects of interventions on
other secondary outcomes described in Table 1. Reports of
thyroid hormone concentrations will be based on bio-
chemical analysis of participant blood samples using stan-
dardised assay methods. PCR will be used for detection of
single nucleotide polymorphisms in thyroid genes. Inter-
ventions reporting quality of life will be based on standar-
dised questionnaires, including generic (e.g. SF-36) or
disease specific questionnaires (e.g. ThySRQ and ThyTSQ).
A p value of less than 0.05 will be used to assess
whether an intervention has had a significant effect on
levothyroxine therapy. This will apply for TSH, T4 and
T3 levels as well as quality of life and other secondary
outcomes as described in Table 1, if provided in an eli-
gible article. Summary values of outcomes will be re-
ported in our systematic review and include means plus
standard deviation and medians plus ranges where pro-
vided. Differences in summary values will be discussed
in the systematic review to assess the effect of factors on
levothyroxine therapy. Comparisons will report factors
that have an effect on levothyroxine therapy compared
to others.
Comparator/control
A control or comparator group is required for studies to
be included in this review, to ensure no potential bias,
experimental errors and to give a baseline or final
comparison.
Search strategy and subject index terms
The keywords hypothyroidism, TSH, food, comorbid,
concomitant, compliance, levothyroxine, drugs and
OATP1, MCT, UGT, FOXE and deiodinase genes
were used in a preliminary search of Web of Science
and obtained a total of 41,242 articles. The results of
this search were evaluated for relevance, and the
search terms were refined accordingly and will be
adapted to the respective database. Due to the broad
nature of this systematic review, six search strategies
have been developed and are displayed in Table 2
using PubMed as an example. Following this, a more
in-depth search of databases EMBASE, Web of Sci-
ence, Cochrane Library and PubMed will be under-
taken. In addition to articles found from database
searches, relevant articles will also be identified from
reference lists of publications.
Outcome measures
Primary outcome
The primary outcome of this review is to identify and
quantify the effect of the listed interventions (clinical,
behavioural and pharmacogenomic) on TSH levels.
Table 2 Search strategy example used in PubMed database
Number Search terms Number of
articles
1 Hypothyroidism OR thyroid stimulating
hormone OR TSH OR levothyroxine OR
LT4 OR thyroid replacement therapy
[Title] [Abstract]
5443
2 Food OR Soy OR Coffee OR Caffeine OR
Fibre [Title] [Abstract]
65014
3 Comorbid OR comorbidity OR lactose
intolerance OR coeliac disease OR celiac
disease OR pernicious anaemia OR
Vitamin B12 deficiency OR anaemia
gastritis OR type 2 diabetes OR
pancreatic disease OR pancreatitis OR
liver disease [Title] [Abstract]
62790
4 Concomitant OR compliance OR
adherence OR levothyroxine AND
dose [Title] [Abstract]
56842
5 Attitudes OR perceptions [Title]
[Abstract]
26370
6 Co-administration OR proton pump
inhibitors OR omeprazole OR
lansoprazole OR lanthanum carbonate
OR calcium AND
medication OR antacids OR sevelamer
hydrochloride OR cholestyramine OR
colesevelam OR ferrous sulphate OR
aluminium hydroxide [Title] [Abstract]
4819
7 OATP1 OR MCT OR UGT OR FOXE OR
deiodinase OR polymorphism
[Title] [Abstract]
32483
8 1 AND 2 890
9 1 AND 3 205
10 1 AND 4 202
11 1 AND 5 10
12 1 AND 6 18
13 1 AND 7 153
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Secondary outcomes
The secondary outcomes (if documented) will be to
quantify the effect of the listed interventions on T4 and
T3 levels. Additional secondary outcome measures will
include any effects upon mortality, morbidity, quality of
life, treatment complications, adverse effects, physical
functioning and social functioning.
Data extraction and synthesis
One review author (RD) will screen titles and abstracts
and remove duplicates. Two reviewers (RD and OO) will
then screen titles and abstracts against inclusion/exclu-
sion criteria. Studies to be included in the review will be
agreed between the two screening reviewers. If there is
disagreement between the reviewers, a third reviewer
(SW) will be consulted. A Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) [23]
flow chart will be constructed. We will construct a data
extraction form and two reviewers (RD and OO) will ex-
tract the data independently and populate the database.
A third reviewer (CMD) may be required for consensus.
The following data will be extracted from articles that
meet the inclusion criteria:
1 Authors, year of publication, country, study design
and number of patients
2 Population demographics
3 Aetiology of hypothyroidism in patient population
4 Co-morbidities in patient population
5 Levothyroxine dose—range/average for each patient
group
6 TSH levels—range/average for each patient group
7 Intervention, type, frequency and duration
Risk of bias (quality) assessment
Two reviewers (RD and OO) will independently assess
each eligible study for risk of bias using the risk of bias
tool in the Cochrane handbook 2011 [24]. This covers
random sequence generation (selection bias), allocation
concealment (selection bias), blinding of participants
and personnel (performance bias), blinding of outcome
assessment (detection bias, patient-reported outcomes
bias and mortality bias), incomplete outcome data ad-
dressed (attrition bias) and selective reporting (reporting
bias). Other forms of bias such as study design bias and
response bias will also be assessed by the reviewers. For
missing data, authors of the eligible studies will be con-
tacted to see if relevant data can be obtained and used
in this systematic review.
Quality of evidence assessment
Eligible articles will be assessed for quality of evidence
referring to the Grading of Recommendations Assess-
ment, Development, and Evaluation (GRADE) guidelines
[25]. Initial ranking of the quality of a study based on
study design, data collection and data analysis will pre-
cede downgrading or upgrading of study quality taking
into account limitations and effect sizes according to the
Cochrane handbook 2011 [24]. A final grade will then be
applied and a score of ‘high’, ‘moderate’, ‘low’ or ‘very low’
will be given to studies as a measure of the quality of
evidence. Any disagreement between reviewers will be
resolved by consulting with a third reviewer (SW).
Strategy for data synthesis
The four-phase flow diagram created will depict the
search strategy used during the review, and the numbers
of articles excluded and included, and on what basis
(PRISMA) [23]. A narrative synthesis of the findings
from the included studies will be provided during this
review. Descriptive summary tables will also be created,
including a summary of all the studies included in the
review and the design and quality assessments of these
studies. The effect measures for the primary and second-
ary outcomes will be summarised. For the main out-
come, effect measures will be the difference in mean or
median TSH and also T3 and T4 where provided. Effect
measures for quality of life (QoL) outcomes will be the
summary difference in QoL questionnaire scores in the
intervention and control arms. For other outcomes such
as morbidity and mortality rates, effect measures will be
the odds ratios (OR) or relative risks (RR) provided.
Meta-analysis plan
We will undertake a meta-analysis of studies in which (i)
there is a defined intervention or exposure, (ii) patients
are receiving levothyroxine for hypothyroidism, (iii) there
is an appropriate control group of levothyroxine treated
patients that are not exposed to the intervention, and (iv)
the primary outcome is determined by serum TSH. Stud-
ies will be included for meta-analysis if adequate informa-
tion is provided, and meta-analysis of a topic will only
proceed if there are sufficient numbers of relevant publi-
cations for the analysis to be meaningful. Studies will
comprise randomised controlled trials as well as observa-
tional data with well-characterised control groups, but
controlled trials and observational data will be pooled sep-
arately. Potential categories of interventions that will be
assessed for meta-analysis include the optimal timing of
levothyroxine administration (e.g. fasting vs non-fasted or
morning vs bed time administration), the effect of con-
comitant drugs such as metformin and anti-epileptic med-
ications on TSH levels, and the impact of co-morbidities
and their treatment on the adequacy of levothyroxine
therapy as determined by TSH levels.
We will determine the pooled difference in TSH
expressed in mU/L (standardised mean difference with
95% confidence intervals) before and after the intervention.
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Unadjusted and adjusted effect sizes will be derived using
a random effects model and inverse variance method. Het-
erogeneity across study results within each category will
be assessed with the I2 test for heterogeneity which will be
graded as follows: I2 values of 0%, no heterogeneity, 25–
50% moderate heterogeneity and 50% high heterogeneity
[26]. We will also assess publication bias with the Egger
test which will be represented graphically using funnel
plots of the standardised mean difference vs the standard
error [27]. However, tests for bias will only be used if there
are at least 10 studies in the meta-analysis, according to
the Cochrane handbook for systematic reviews of inter-
ventions [28]. Statistical analysis will be undertaken with
the Review Manager Software, version 5.2, The Nordic
Cochrane Centre, The Cochrane Collaboration, 2012 [29].
Discussion
This review seeks to further the understanding of the var-
iety of factors that affect the adequacy of thyroid hormone
replacement in patients diagnosed with hypothyroidism.
The aim is to provide evidence to explain why patients ex-
perience TSH levels that are outside the normal reference
range and to help healthcare professionals to better target
areas to improve TSH control. Understanding the effects
of various factors on TSH levels may help to comprehend
why certain individuals are unhappy with their levothyrox-
ine treatment.
This protocol has defined the search strategy to achieve
the aims of the systematic review, how results will be eval-
uated, and how bias (Cochrane handbook [24]) and qual-
ity of evidence (GRADE) will be assessed. We have
described patients, interventions, comparisons, outcomes,
and study design (PICOS). We chose TSH levels as our
primary outcome, and we acknowledge and will assess the
effects upon T4 and T3 levels. Other significant secondary
outcomes to be addressed include mortality, morbidity,
quality of life, treatment complications, adverse effects,
physical functioning and social functioning. Evidence from
all potential studies will be initially accepted to give a
broad approach that is necessary for our review.
The systematic review will be reported according to
the PRISMA guidelines. This will be the first systematic
review to focus on quantifying the effects of clinical, be-
havioural and pharmacogenomic factors on TSH levels
in patients with primary hypothyroidism or subclinical
hypothyroidism. Findings will be disseminated at confer-
ences and in professional and peer-reviewed journals.
Additional file
Additional file 1: Word document (62 KB). Preferred Reporting Items for
Systematic Reviews and Meta-Analyses: The PRISMA statement. This file
contains a 27-item checklist of recommended items to include in a
systematic review and meta-analysis. (DOC 62 kb)
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